ARTICLE | Company News
Immunomedics, UCB deal
March 14, 2016 7:00 AM UTC
Immunomedics said UCB discontinued development of epratuzumab ( IMMU-103) and terminated a May 2006 deal that gave UCB exclusive rights to develop and commercialize the compound for autoimmune indicat...